Calamos Advisors
CRL icon

Calamos Advisors’s Charles River Laboratories CRL Stock Holding History

Calamos Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-41,960
Closed -$2.67M – 694
2014
Q4 		$2.67M Sell
41,960
-250
-0.6% -$15.7K 0.02% 436
2014
Q3 		$2.52M Sell
42,210
-830
-2% -$47.5K 0.02% 420
2014
Q2 		$2.3M Buy
+43,040
New +$2.36M 0.01% 441

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Calamos Advisors's CRL Position: Q1 2015 in Review

Calamos Advisors sold out of Charles River Laboratories (CRL) in Q1 2015, closing a stake of 41,960 shares — an estimated $2.67M sold.

Calamos Advisors first reported a position in CRL in Q2 2014 and held it in 3 quarters. The position peaked at $2.67M in Q4 2014. 259 funds tracked by Wall St. Rank hold CRL as of Q1 2015.

  • Calamos Advisors reported no remaining Charles River Laboratories position as of Q1 2015 after selling out during the quarter.
  • Calamos Advisors sold 41,960 Charles River Laboratories shares in Q1 2015, an estimated $2.67M.
  • Calamos Advisors first reported a position in Charles River Laboratories in Q2 2014 and held it in 3 quarters.
  • Calamos Advisors's Charles River Laboratories position peaked at $2.67M in Q4 2014.
  • 259 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2015.

Based on Calamos Advisors's 13F filing for Q1 2015, filed 13 May 2015.